Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Colonic Neoplasms 2Solid Tumor 1Rectal Neoplasms 1Multiple Myeloma 1Lymphoma 1Diabetes Mellitus, Type 2 1Colorectal Neoplasms 1

Interventions

pembrolizumab 14Injections 13Paclitaxel 10Nivolumab 10Docetaxel 9Cisplatin 9Capecitabine 8Bevacizumab 8toripalimab 7senaparib 7Cyclophosphamide 7tislelizumab 6atezolizumab 6Irinotecan 6Gemcitabine 5Fluorouracil 5fludarabine 4apatinib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorodeoxyglucose F18 4spartalizumab 3pertuzumab 3olaparib 3camrelizumab 3Rifampin 3Radiosurgery 3Midazolam 3Itraconazole 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Tumor × Resistant Starch × Clear all
NCT04552418 2024-02-28

Intestinal Microbiome Modification With Resistant Starch in Patients Treated With Dual Immune Checkpoint Inhibitors

University of Michigan Rogel Cancer Center

Phase EARLY_PHASE1 Completed
12 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡